The CMA has alleged that Concordia and Actavis signed illegal agreements which enabled high prices for a life-saving drug to be prolonged. Naturally the announcement has brought a wave of criticism for the businesses involved because the cost of higher prices for drugs routinely used in the NHS are ultimately paid for by the taxpayer.

Two pharmaceutical firms accused of driving up prices of an NHS life-saving drug with secret deal https://t.co/ovzRkL6P6j
— The Independent (@Independent) March 3, 2017

Share:

Geoff Riley

Geoff Riley FRSA has been teaching Economics for over thirty years. He has over twenty years experience as Head of Economics at leading schools. He writes extensively and is a contributor and presenter on CPD conferences in the UK and overseas.

Our subjects

Explore

Contact

Boston House,
214 High Street,
Boston Spa,
West Yorkshire,
LS23 6AD

Tel: +44 0844 800 0085